
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
MaxCyte Inc (MXCT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MXCT (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $7
1 Year Target Price $7
6 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.82% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.12M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6 | Beta 0.3 | 52 Weeks Range 2.00 - 5.20 | Updated Date 06/30/2025 |
52 Weeks Range 2.00 - 5.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-06-11 | When After Market | Estimate -0.13 | Actual -0.1 |
Profitability
Profit Margin -110.92% | Operating Margin (TTM) -118.34% |
Management Effectiveness
Return on Assets (TTM) -13.12% | Return on Equity (TTM) -19.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 113389585 | Price to Sales(TTM) 6.21 |
Enterprise Value 113389585 | Price to Sales(TTM) 6.21 | ||
Enterprise Value to Revenue 3.01 | Enterprise Value to EBITDA -11.07 | Shares Outstanding 106319000 | Shares Floating 95138075 |
Shares Outstanding 106319000 | Shares Floating 95138075 | ||
Percent Insiders 1.45 | Percent Institutions 75.79 |
Analyst Ratings
Rating 3 | Target Price 7 | Buy - | Strong Buy 6 |
Buy - | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MaxCyte Inc
Company Overview
History and Background
MaxCyte Inc. was founded in 1998. The company pioneered flow electroporation technology and has focused on enabling cell-based research, development, and manufacturing of innovative cell therapies.
Core Business Areas
- ExPERT Platform: The core technology platform. It is a flow electroporation technology that enables complex cell engineering for cell therapy and drug discovery. Provides delivery of a wide range of molecules into cells. Revenue model involves sales of instruments, disposables, and service contracts.
- CARMA Platform: CARMA is MaxCyte's own cell therapy development pipeline, with a focus on targeting difficult-to-treat cancers. While not the primary revenue driver currently, it represents future potential.
- Strategic Partnerships: MaxCyte partners with leading biopharmaceutical companies, granting them access to its technology through Strategic Platform Licenses (SPLs). These licenses generate recurring revenue via milestone payments and royalties on sales of therapies developed using the MaxCyte platform.
Leadership and Structure
Doug Doerfler is the President and CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- ExPERT Platform: Flow electroporation technology enabling cell engineering. MaxCyte holds a strong position in this niche market, but specific market share data is challenging to obtain. Competitors include Lonza, Thermo Fisher Scientific (although they do not compete directly), and smaller companies developing alternative transfection methods. Revenue from this is in form of sale of the instruments and the associated supplies for usage.
- Strategic Platform Licenses (SPLs): Allows partners to use MaxCyte's technology to develop their cell therapies. Revenue is generated from upfront payments, milestone payments, and royalties on sales of approved therapies. No direct competitor in this field. Strategic platform licenses include BMS, CRISPR Therapeutics, Vertex, and others.
Market Dynamics
Industry Overview
The cell therapy and gene editing industries are experiencing rapid growth, driven by advances in technology and increasing demand for novel treatments for cancer and other diseases.
Positioning
MaxCyte is positioned as a key enabling technology provider for cell therapy development. Its flow electroporation technology offers advantages in terms of efficiency, scalability, and cell viability, giving it a competitive edge.
Total Addressable Market (TAM)
The cell therapy market is projected to reach billions of dollars in the coming years. MaxCyte is positioned to capture a significant portion of this market by providing its technology to leading cell therapy developers.
Upturn SWOT Analysis
Strengths
- Proprietary and differentiated technology (flow electroporation)
- Strong intellectual property portfolio
- Established partnerships with leading biopharmaceutical companies
- Recurring revenue stream from SPLs
- CARMA internal therapeutic development pipeline
Weaknesses
- Reliance on partners' success for royalty revenue
- CARMA development is in early stages and has high risk
- Cash burn rate and potential need for future financing
- Competition from alternative transfection technologies
Opportunities
- Expansion of SPL partnerships
- Advancement of CARMA pipeline
- Increasing adoption of cell therapies
- Development of new applications for flow electroporation
- Market growth in gene editing
Threats
- Clinical trial failures of partners' cell therapies
- Emergence of competing transfection technologies
- Regulatory challenges in the cell therapy space
- Economic downturn impacting biopharmaceutical R&D spending
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- LON: LNZ
- TMO
Competitive Landscape
MaxCyte has a strong position in flow electroporation, offering advantages over traditional methods. Competition exists from companies developing alternative transfection technologies, but MaxCyte's established partnerships and proprietary technology provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: MaxCyte has shown significant growth in revenues over the years, driven by SPL agreements. However, revenue can fluctuate depending on partner milestones.
Future Projections: Analyst projections anticipate continued revenue growth driven by new SPLs, milestone payments, and potential royalties from approved therapies. However, there are uncertainties linked to regulatory approvals and clinical outcomes.
Recent Initiatives: Recent initiatives include new partnerships, advancement of the CARMA pipeline, and expansion of the ExPERT platform.
Summary
MaxCyte is a promising biotechnology company focused on enabling cell-based therapies through its flow electroporation technology. Its strength lies in the strategic partnerships and recurring revenue, but the dependence on the success of its partners and the cash burn rate are weaknesses. The company needs to carefully monitor its cash usage and expand its application of its Expert platform. The growth projections are optimistic, but the market has its own challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MaxCyte Inc. SEC Filings, Investor Presentations, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimations and industry reports. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MaxCyte Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-07-30 | President, CEO & Executive Director Mr. Maher Masoud | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114 | Website https://www.maxcyte.com |
Full time employees 114 | Website https://www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.